| |
Prevalence of Genotypic Drug Resistance Among a Cohort of HIV-Infected
Newborns: suggesting resistance testing in newborns
|
| |
| |
A retrospective, blinded study was conducted to examine the prevalence of
antiretroviral drug resistance among a cohort of HIV-infected infants born in
1998 and 1999 in New York State. The earliest available HIV-positive specimen
was tested. Most samples were from infants younger than 60 days of age.
Genotype data were generated for the protease and reverse transcriptase genes
of HIV-1 proviral DNA from 91 infected infants. Eleven infants (12.1%) had
provirus with mutations associated with drug resistance, with all three
classes of antiretroviral drugs represented. Two infants (2.2%) had mutations
associated with resistance to two classes of antiretrovirals. Perinatal
antiretroviral drug exposure was examined; it was not found to be
significantly associated with the presence of resistance mutations. However,
for those infants who had perinatal antiretroviral exposure and genotypic
evidence of drug resistance to HIV, the mutations that were detected
correlated with at least one antiretroviral from the perinatal period. The
prevalence of genotypic drug resistance among this infant cohort is
comparable with that found among recently infected adults. These results
suggest that resistance testing
should be strongly considered for perinatally infected infants, at the
earliest possible time point, to avoid use of antiretroviral drugs to which
the infant has preexisting resistance.
J Acquir Immune Defic Syndr 2003 Mar 1;32(3):292-7
Parker MM, Wade N, Lloyd Jr RM, Birkhead GS, Gallagher BK, Cheku B, Sullivan
T, Taylor J.
|
|
| |
| |
|
|
|
